‹ ›
MYP_088115
← PREVIOUS NEXT → BACK
Basic Information
C34
Antimicrobial
Antiviral
Antiviral ▸ Anti-HIV
Antiviral ▸ Anti-HIV ▸ Anti-HIV-1
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition ▸ Fusion inhibitor
Standard
34 amino acids
C184H280N50O64S
Standard
Sequence
WMEWDREINNYTSLIHSLIEESQNQQEKNEQELL
Physicochemical Analysis
4248.55 Da
4.21
-6.13
-6.40
-0.1804
-1.27
0.58
-0.20
71.11
80.29
0.0882
12490.00
12490.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
1916.07
-18.32
63.0
60.0
147.0
299.0
6.0
41.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0252085 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Cathelicidin
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral
HIV-1 NL4-3 DelV4/D36G/I37K/N126K/L204I
PMID19114674;27795416;31805154;12203417 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/19114674/
RECORD: Rec_0259037 VERIFIED: YES
Provenance & Taxonomy
not reported [other]
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Antiviral
PaperHIPdb: a database of experimentally validated HIV inhibiting peptides PMID23359817 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/23359817/
RECORD: Rec_0286530 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HIV gp41 HR2 fusion inhibitor
32630.0
Structure & Mods
synthetic linear peptide [Linear]
mixed L/D amino-acid peptide [Mixed]
Acetylation
Amidation
Bio-Activity Profile
Antiviral Anti-HIV Fusion inhibitor
HIV, Simian immunodeficiency virus
PaperC34, a membrane fusion inhibitor, blocks HIV infection of langerhans cells and viral transmission to T cells; Patent: Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity PMID17255952 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/17255952/ PatentUS 7575750 B2
RECORD: Rec_0301915 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Anti-HIV-1 Fusion inhibition
HIV-1 (NL4-3N43D) | HeLa cells
0.023±0.005 μM
EC50
Mammalian: 2.8 h; Yeast: 3 min; E. coli: 2 min
PaperDesign of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. | Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M. | J Biol Chem. 2009 Feb 20;284(8):4914-20. | DOI:10.1074/jbc.M807169200 | PMID:19073606 PMID19073606 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/19073606/
RECORD: Rec_0324077 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Cathelicidin
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral
HIV-1 NL4-3 D36G/N43D/S138A
PMID19114674;27795416;31805154;12203417 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/19114674/
FIRST PREV 1 2 3 4 5 6 NEXT LAST
Showing 5 records on this page · Page 4 of 6